Cysteamine therapy for children with nephropathic cystinosis.
about
Identification and characterisation of the murine homologue of the gene responsible for cystinosis, CtnsIdentification and subcellular localization of a new cystinosin isoformThe promoter of a lysosomal membrane transporter gene, CTNS, binds Sp-1, shares sequences with the promoter of an adjacent gene, CARKL, and causes cystinosis if mutated in a critical regionCTNS mutations in an American-based population of cystinosis patientsSialic acid storage diseases. A multiple lysosomal transport defect for acidic monosaccharidesCystinosis: a reviewCystinosis: the evolution of a treatable diseaseNephropathic cystinosis: an international consensus documentCTNS mutations in patients with cystinosisQuantitative in vivo and ex vivo confocal microscopy analysis of corneal cystine crystals in the Ctns knockout mouseEndo-lysosomal dysfunction in human proximal tubular epithelial cells deficient for lysosomal cystine transporter cystinosinIntralysosomal cystine accumulation in mice lacking cystinosin, the protein defective in cystinosisUpregulation of the Rab27a-dependent trafficking and secretory mechanisms improves lysosomal transport, alleviates endoplasmic reticulum stress, and reduces lysosome overload in cystinosis.Clearance of corneal crystals in nephropathic cystinosis by topical cysteamine 0.5%.Worldwide view of nephropathic cystinosis: results from a survey from 30 countriesOral cysteamine bitartrate and N-acetylcysteine for patients with infantile neuronal ceroid lipofuscinosis: a pilot studyPharmacokinetics of enteric-coated cysteamine bitartrate in healthy adults: a pilot study.Cystinosis: practical tools for diagnosis and treatmentEnzyme replacement therapy and beyond-in memoriam Roscoe O. Brady, M.D. (1923-2016).Cysteamine (Cystagon®) adherence in patients with cystinosis in Spain: successful in children and a challenge in adolescents and adults.A multicentre randomised double masked clinical trial of a new formulation of topical cysteamine for the treatment of corneal cystine crystals in cystinosis.Effects of oral phosphocysteamine and rectal cysteamine in cystinosis.Ophthalmic manifestations and histopathology of infantile nephropathic cystinosis: report of a case and review of the literature.Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome.Improvement in the renal prognosis in nephropathic cystinosisPharmacokinetics of cysteamine bitartrate following gastrointestinal infusion.Cysteamine therapy: a treatment for cystinosis, not a cure.Genetic basis of cystinosis in Turkish patients: a single-center experience.Nephropathic cystinosis: late complications of a multisystemic disease.Substrate Reduction Therapy in Four Patients with Milder CLN1 Mutations and Juvenile-Onset Batten Disease Using Cysteamine Bitartrate.Chemical individuality: concept and outlook.Improving the prognosis of nephropathic cystinosis.Cystinosis: a new perspective.Evaluation of topical cysteamine therapy in the CTNS(-/-) knockout mouse using in vivo confocal microscopy.Pharmacokinetic Studies of Cysteamine Bitartrate Delayed-Release.A study of the relative bioavailability of cysteamine hydrochloride, cysteamine bitartrate and phosphocysteamine in healthy adult male volunteers.Growth hormone producing prolactinoma in juvenile cystinosis: a simple coincidence?Bartter syndrome associated with nephropathic cystinosis.Hirschsprung's disease with infantile nephropathic cystinosis.A cost-effectiveness analysis of the orphan drug cysteamine in the treatment of infantile cystinosis.
P2860
Q21283771-30C6D25E-451D-46E1-85DF-ED30106F1E79Q24310549-DB90470F-70ED-4C2E-A231-9524AB8A448CQ24533355-7CAA2CAC-1EF1-4C79-BDDD-6D38EEDE4F94Q24539471-E5AC78AE-7E5C-4133-9E56-50E6CF2D4732Q24633782-3C777ACD-833F-4D88-9F3E-7EC5E9EDC34CQ26751225-9AAEF21F-68F8-4DC1-91D3-4E0AB4D20EC5Q26863651-394449BE-7A9A-4E94-B746-76FD8CF54607Q27024508-4FE972F5-4DB1-4B41-B71A-248F612E7285Q28138498-B7FC9518-2B3C-4D07-B766-C4A18E34ACD1Q28506311-E1DD2A0A-329C-4F28-912C-2F7BA34A5E88Q28545059-4B5025D8-0CCB-44B1-95ED-9F1BBB3498AEQ28591791-061481C7-7CD3-4B84-8D40-986D0B1713A5Q30541728-206CE821-7179-485B-8D5B-4C6544E3C306Q33648729-ED984CCE-4575-44F5-B996-60116902F2C4Q33869391-733415AC-E1C3-49FC-AB31-4A4B37F11E08Q34072762-5E9C9793-74F4-4599-952D-D82FE76A2F6FQ34174907-572A49E4-2825-4C9F-91F1-87D53CB1A5B7Q34467739-ED6ED21D-2844-4375-86C5-A3988F9E63D2Q34553589-EA769008-C897-4B34-A5D0-17A316AD3AD4Q35119039-465A0A09-19D6-457A-9FA8-25934D5AF134Q35590454-1BEDEB43-A30C-469C-821D-2FC4385E0D57Q35627299-1B321DE7-9461-4BEC-9DC7-0EE2BABC6D88Q35748378-1FB9E3B3-F6E4-468E-9AFB-9E1A9963C6C9Q35809990-31D2671D-7A8D-4885-B3F3-FD630A517278Q35985812-1A625ACE-E616-408C-B7B3-B59042056977Q36024965-66884AF9-8B3F-4DC5-8EB5-E73F54785495Q36068161-0DF038D9-AE71-4A23-8E6C-F7DAD84A12F5Q36410885-B2FE5672-E589-4CC5-9ACC-367B742E887DQ37002855-A8E0DE8A-9F79-4E0E-AFE7-57ED81EEB1B3Q37127591-1DAC4C93-854C-4CD1-9835-7D68F6A45C27Q37287431-D16652E4-9D09-4F18-A4F3-55EC1EDEC4CEQ38239120-A8427CA7-F03C-4A0D-9602-C3D649DE1C5EQ38307845-86F97173-31F4-4E51-8186-A38F66A1B023Q38961757-FCDE1B1C-AC1B-4F37-99D0-8C84FFA1A37EQ39816343-53980A70-3C80-4DE7-B9A1-CC80F1C99CF5Q41592515-1B419092-35C9-4039-B433-87DB6300DDA9Q41786211-B72FFA1E-FD6F-41FE-AE6E-FA8B19E71D42Q42025812-B440E5ED-8B20-4EFC-B32F-34AD0978A654Q42402667-78AE83BB-4D7F-4EDC-8D22-2637C6D2D3C7Q43650454-587BDB52-08AB-4DA2-B498-D6A9058C89FA
P2860
Cysteamine therapy for children with nephropathic cystinosis.
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
1987年學術文章
@zh
1987年學術文章
@zh-hant
name
Cysteamine therapy for children with nephropathic cystinosis.
@en
Cysteamine therapy for children with nephropathic cystinosis.
@nl
type
label
Cysteamine therapy for children with nephropathic cystinosis.
@en
Cysteamine therapy for children with nephropathic cystinosis.
@nl
prefLabel
Cysteamine therapy for children with nephropathic cystinosis.
@en
Cysteamine therapy for children with nephropathic cystinosis.
@nl
P2093
P1476
Cysteamine therapy for children with nephropathic cystinosis.
@en
P2093
Schlesselman JJ
Schneider JA
Schulman JD
P304
P356
10.1056/NEJM198704163161602
P407
P577
1987-04-01T00:00:00Z